Bert Jan H van Den Born

Bert Jan H van Den Born

Auto-generated profile, based on publicly available information

Bert Jan H van Den Born

Amsterdam UMC

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in European Heart Journal
Verified
Journal Article
Open access
PDF file
Barbara VerhaarBarbara Verhaar
Barbara Verhaar
DCDidier Collard
Didier Collard
APAndrei Prodan
Andrei Prodan
JLJohannes H M Levels
Johannes H M Levels
AZAeilko H Zwinderman
Aeilko H Zwinderman
BBBert-Jan H van Den Born
Bert-Jan H van Den Born
Preliminary evidence from animal and human studies shows that gut microbiota composition and levels of microbiota-derived metabolites, including short-chain fatty acids (SCFAs), are associated with blood pressure (BP). We hypothesized that faecal microbiota composition and derived metabolites may be differently associated with BP across ethnic groups. We included 4672 subjects (mean age 49.8 ± 11.7 years, 52% women) from six different ethnic groups participating in the HEalthy Life In an Urban Setting (HELIUS) study. The gut microbiota was profiled using 16S rRNA gene amplicon sequencing. Associations between microbiota composition and office BP were assessed using machine learning prediction models. In the subgroups with the largest associations, faecal SCFA levels were compared in 200 subjects with lower or higher systolic BP. Faecal microbiota composition explained 4.4% of the total systolic BP variance. Best predictors for systolic BP included Roseburia spp., Clostridium spp., Romboutsia spp., and Ruminococcaceae spp. Explained variance of the microbiota composition was highest in Dutch subjects (4.8%), but very low in South-Asian Surinamese, African Surinamese, Ghanaian, Moroccan and Turkish descent groups (explained variance <0.8%). Faecal SCFA levels, including acetate (P < 0.05) and propionate (P < 0.01), were lower in young Dutch participants with low systolic BP. Faecal microbiota composition is associated with BP, but with strongly divergent associations between ethnic groups. Intriguingly, while Dutch participants with lower BP had higher abundances of several SCFA-producing microbes, they had lower faecal SCFA levels. Intervention studies with SCFAs could provide more insight in the effects of these metabolites on BP.

23 June 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
PJPatrick A. de Jonge
Patrick A. de Jonge
KWKoen Wortelboer
Koen Wortelboer
TSTorsten P. M. Scheithauer
Torsten P. M. Scheithauer
BBBert-Jan H. van Den Born
Bert-Jan H. van Den Born
AZAeilko H. Zwinderman
Aeilko H. Zwinderman
HHHilde Herrema
Hilde Herrema
There is significant interest in altering the course of cardiometabolic disease development via gut microbiomes. Nevertheless, the highly abundant phage members of the complex gut ecosystem -which impact gut bacteria- remain understudied. Here, we show gut virome changes associated with metabolic syndrome (MetS), a highly prevalent clinical condition preceding cardiometabolic disease, in 196 participants by combined sequencing of bulk whole genome and virus like particle communities. MetS gut viromes exhibit decreased richness and diversity. They are enriched in phages infecting Streptococcaceae and Bacteroidaceae and depleted in those infecting Bifidobacteriaceae. Differential abundance analysis identifies eighteen viral clusters (VCs) as significantly associated with either MetS or healthy viromes. Among these are a MetS-associated Roseburia VC that is related to healthy control-associated Faecalibacterium and Oscillibacter VCs. Further analysis of these VCs revealed the Candidatus Heliusviridae, a highly widespread gut phage lineage found in 90+% of participants. The identification of the temperate Ca. Heliusviridae provides a starting point to studies of phage effects on gut bacteria and the role that this plays in MetS.

5 April 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
RBRomain Boulestreau
Romain Boulestreau
BBBert‐Jan H. van Den Born
Bert‐Jan H. van Den Born
Gregory LipGregory Lip
Gregory Lip
AGAjay K. Gupta
Ajay K. Gupta
Malignant hypertension is a hypertensive emergency, with rapid disease progression and poor prognosis. Although recognized as a separate entity more than a century ago, significant knowledge gaps remain about its pathogenesis and treatment. This narrative review summarizes current viewpoints, research gaps, and challenges with a view to pooling future efforts at improving treatment and prognosis.

1 May 2020 in Hypertension
Verified
Journal Article
Open access
PDF file
DCDidier Collard
Didier Collard
TBTom F. Brouwer
Tom F. Brouwer
RERik Olde Engberink
Rik Olde Engberink
AZAeilko H. Zwinderman
Aeilko H. Zwinderman
LVLiffert Vogt
Liffert Vogt
BBBert-Jan H. van Den Born
Bert-Jan H. van Den Born
Lowering blood pressure (BP) can lead to an initial decline in estimated glomerular filtration rate (eGFR). However, there is debate how much eGFR decline is acceptable. We performed a post hoc analysis of ACCORD-BP (Action to Control Cardiovascular Risk in Diabetes-Blood Pressure) and SPRINT (Systolic Blood Pressure Intervention Trial), which randomized patients to intensive or standard systolic BP-targets. We determined the relation between initial decline in mean arterial pressure and eGFR. Subsequently, we stratified patients to BP-target and initial eGFR decrease and assessed the relation with annual eGFR decline after 1 year. A total of 13 266 patients with 41 126 eGFR measurements were analyzed. Up to 10 mm Hg of BP-lowering, eGFR did not change. Hereafter, there was a linear decrease of 3.4% eGFR (95% CI, 2.9%–3.9%) per 10 mm Hg mean arterial pressure decrease. The observed eGFR decline based on 95% of the subjects varied from 26% after 0 mm Hg to 46% with a 40 mm Hg mean arterial pressure decrease. There was no difference in eGFR slope ( P =0.37) according to initial eGFR decline and BP-target, with a decrease of 1.24 (95% CI, 1.09–1.39), 1.20 (95% CI, 0.97–1.43), and 1.14 (95% CI, 0.77–1.50) in the 5%, 5% to 20%, and >20% stratum during intensive and 0.95 (95% CI, 0.81–1.09), 1.23 (95% CI, 0.97–1.49), and 1.17 (95% CI, 0.65–1.69) mL/minute per 1.73 m 2 per year during standard treatment. In patients at high cardiovascular risk with and without diabetes mellitus, we found no association between initial eGFR and annual eGFR decline during BP-lowering treatment. Our results support that an eGFR decrease up to 20% after BP lowering can be accepted and suggest that the limit can be extended up to 46% depending on the achieved BP reduction. Registration—: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00000620, NCT01206062.

1 October 2024 in Hypertension
Verified
Journal Article
Open access
Barbara VerhaarBarbara Verhaar
Barbara Verhaar
MWMadelief Wijdeveld
Madelief Wijdeveld
KWKoen Wortelboer
Koen Wortelboer
Elena RampanelliElena Rampanelli
Elena Rampanelli
JLJohannes H.M. Levels
Johannes H.M. Levels
MMMajon Muller
Majon Muller
BACKGROUND: The microbiota-derived short chain fatty acid butyrate has been shown to lower blood pressure (BP) in rodent studies. Nonetheless, the net effect of butyrate on hypertension in humans remains uncovered. In this study, for the first time, we aimed to determine the effect of oral butyrate on BP in patients with hypertension. METHODS: We performed a double-blind randomized placebo-controlled trial including 23 patients with hypertension. Antihypertensive medication was discontinued for the duration of the study with a washout period of 4 weeks before starting the intervention. Participants received daily oral capsules containing either sodium butyrate or placebo with an equivalent dosage of sodium chloride for 4 weeks. The primary outcome was daytime 24-hour systolic BP. Differences between groups over time were assessed using linear mixed models (group-by-time interaction). RESULTS: Study participants (59.0±3.7 years; 56.5% female) had an average baseline office systolic BP of 143.5±14.6 mm Hg and diastolic BP of 93.0±8.3 mm Hg. Daytime 24-hour systolic and diastolic BP significantly increased over the intervention period in the butyrate compared with the placebo group, with an increase of +9.63 (95% CI, 2.02–17.20) mm Hg in daytime 24-hour systolic BP and +5.08 (95% CI, 1.34–8.78) mm Hg in diastolic BP over 4 weeks. Butyrate levels significantly increased in plasma, but not in feces, upon butyrate intake, underscoring its absorption. CONCLUSIONS: Four-week treatment with oral butyrate increased daytime systolic and diastolic BP in subjects with hypertension. Our findings implicate that butyrate does not have beneficial effects on human hypertension, which warrants caution in future butyrate intervention studies. REGISTRATION: URL: https://onderzoekmetmensen.nl/ ; Unique identifier: NL8924.

7 May 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
Charles AgyemangCharles Agyemang
Charles Agyemang
ELEva L. van der Linden
Eva L. van der Linden
FCFelix Chilunga
Felix Chilunga
BBBert‐Jan H. van Den Born
Bert‐Jan H. van Den Born
Europe and North America are the 2 largest recipients of international migrants from low‐resource regions in the world. Here, large differences in cardiovascular disease (CVD) morbidity and death exist between migrants and the host populations. This review discusses the CVD burden and its most important contributors among the largest migrant groups in Europe and North America as well as the consequences of migration to high‐income countries on CVD diagnosis and therapy. The available evidence indicates that migrants in Europe and North America generally have a higher CVD risk compared with the host populations. Cardiometabolic, behavioral, and psychosocial factors are important contributors to their increased CVD risk. However, despite these common denominators, there are important ethnic differences in the propensity to develop CVD that relate to pre‐ and postmigration factors, such as socioeconomic status, cultural factors, lifestyle, psychosocial stress, access to health care and health care usage. Some of these pre‐ and postmigration environmental factors may interact with genetic (epigenetics) and microbial factors, which further influence their CVD risk. The limited number of prospective cohorts and clinical trials in migrant populations remains an important culprit for better understanding pathophysiological mechanism driving health differences and for developing ethnic‐specific CVD risk prediction and care. Only by improved understanding of the complex interaction among human biology, migration‐related factors, and sociocultural determinants of health influencing CVD risk will we be able to mitigate these differences and truly make inclusive personalized treatment possible.